Introduction

Influenza, belonging to the family Orthomyxoviridae, primarily affects the respiratory system and represents one of the most frequent causes of acute upper respiratory tract infections during the winter season [1,2]. Although the infection is usually self-limiting, children have a higher risk of complications [3]. Neurological complication, often defined as Influenza-Associated Encephalitis/Encephalopathy (IAE), is rare but is an important complication of influenza infection with approximately three-quarters of cases regarding children and leading up to 30% of mortality in children [1,4,5].

For including a variety of acute encephalopathy syndromes and lacking available biomarkers, it is difficult to diagnose or predict the outcome of IAE. Neurological signs/symptoms caused by influenza include mild altered mental status, vertigo, epileptic status, meningitis, and demyelinating disease [6-9]. Age less than 5 years, history with comorbid disease was found to be the risk factors for severe IAE [6]. At present, there are few studies of mortality risk factors in large samples of children with IAE.

Therefore, in this study, we analyzed the mortality risk factors of IAE in children admitted to Guangzhou Women and Children's Medical Center in 2016-2019. Through the early identification of high-risk factors, pediatricians could make timely interventions to promote prognosis.

Methods

Patients

This study included 68 patients with IAE who were admitted to Guangzhou Women and Children's Medical Center between January 2016 and December 2019. All patients were nasal and pharyngeal swab specimen positive for influenza virus A or B in by real-time
reverse transcriptase-polymerase chain reaction (RT-PCR). The ethics committee approved this study of Guangzhou Women and Children’s Medical Center, Guangzhou Medical University (Sui, Fuer, Kelun (2019), NO 38201). Individual written informed consent was obtained from the patients’ parents or guardians.

The inclusion criteria: 1) <14 years of age; 2) positive real-time PCR detection of influenza virus in nasal and pharyngeal swabs; and 3) presence of symptoms and signs of nervous system injury, such as seizures, rapid cognitive impairment, ADOC or coma.

The exclusion criteria: 1) co-infection with other infections such as herpes simplex virus, cytomegalovirus, or bacteria; 2) with serious comorbidities such as immune deficiency, metabolic disorders, trauma, cerebrovascular disease, or brain tumor; 3) congenital neurological malformation or syndrome; or 4) any inherited condition affecting the neurological functions.

Definition of neurological complications

The definition of IAE includes the following criteria [10-12]: sudden onset of symptoms of influenza, and respiratory specimen positive for an influenza virus; the emergence or development of a neurological symptom in influenza infection, such as convulsion, alteration of consciousness, rapidly progressive coma; the abnormal neuroradiological finding in Neuroimaging, including edema, hemorrhage, and bilateral thalamic lesions, as well as electroencephalography showing a diffuse slowing of the background activity; exclusion of infection from other pathogens or non-infectious diseases such as metabolic disorders, trauma, cerebrovascular disorders, and/or brain tumors.

Data collection

We take the retrospective method in this study. Data on demographics, clinical presentation, laboratory findings, microbiologic and neuroimaging findings, treatment, response to therapy and outcome were collected. Demographic data included age, gender, onset month. Clinical data included fever (peak temperature and time of fever lasting), respiratory symptoms, headache, vomiting, and neurological symptoms (convulsion, ADOC, rapidly progressive coma). Results of routine blood test, the comprehensive metabolic panel (CMP), routine and biochemical test in CSF, and pathogenetic test in blood/ nasal swabs/CSF were collected on admission day as laboratory and microbiologic data. And neuroimaging data included CT and MRI, diagnosed by a senior pediatric radiologist (more than ten years experiences), and were reviewed again for IAE.

Data analyses

All statistical analyses were performed using the SPSS 22.0 software (IBM Corp., Armonk, NY, USA). Categorical data were presented as frequency with the corresponding percentage, and continuous data were presented as median with the Interquartile Range (IQR). The Chi-squared or Fisher exact test was used to compare categorical variables. To determine the independent contribution of each factor to the case outcomes, multiple logistic regression analysis was performed. Two-tailed P-values of <0.05 were considered statistically significant.

Results

Demographics and clinical characteristics

There was a total of 68 patients with IAE in this study, 40 males and 28 females, aged 3 months to 13 years, of whom 66.18% (45/68) were younger than 5 years old, were not vaccinated against influenza and had no underlying disease. The patients’ main clinical manifestations at the time of admission were fever, convulsions, Acute Disturbance of Consciousness (ADOC), and vomiting. IAE occurred mainly in January (7 cases), February (8 cases), March (11 cases), June (9 cases), and December (13 cases). The patients were divided into survival and non-survival groups according to clinical outcome. We observed 20.5% patients (14 cases) dead in this research, of which the proportion of children with temperature >39°C, ADOC and cardiac arrest was significantly higher in the non-survival group. 100% vs. 51.85% P<0.05, 100% vs. 40.7% P<0.001, 1.85% vs. 35.7% P<0.05 (Table 1) and the proportion of children requiring tracheal intubation with ventilator-assisted ventilation was significantly higher in the non-survival group compared to the survival group. 35.7% vs. 1.85% P<0.05.

Laboratory findings

In this study, the median white blood cell count in laboratory tests was 8.55 (2.4-29.6)×10^9/L. In all cases, there were 39.71% patients (27/68) with elevated Alanine Aminotransferase (ALT), 52.94% patients (36/68) with elevated Aspartate Aminotransferase (AST), 38.24% patients (26/68) with elevated Creatine Kinase (CK), 58.82% patients (40/68) with elevated Lactate Dehydrogenase (LDH), and both 53.45% patients (31/68) with elevated C-Reactive Protein (CRP) or lactate. Comparing to the survival group, there was a statistically significant elevation of ALT, AST, CK, LDH, CRP, and LDH in the non-survival group (P<0.05), as shown in Table 1. The median CSF protein in the non-survival group and survival group was respectively 1.90g/L (0.12-34.5) and 0.34g/L (0.12-12.4). The difference between the two groups was statistically significant (P<0.05).

Neuroimaging findings

In this study, except for 4 patients who failed to complete neuroimaging examination due to their unstable condition, the other 64 cases underwent brain CT or MRI. The typical brain MRI in children with IAE could be found in some patients, presenting symmetric high signal in the bilateral thalamus, basal ganglia, medulla oblongata, pontocerebellar and cerebellum as shown in Figure 1. But the other showed various and non-specific manifestations, which may show scattered abnormal signal shadows in the cerebral hemispheres, cerebral edema, and some, did not show apparent abnormalities (Figure 2).

Treatment

After admission, the patients were routinely monitored and given temperature reduction and anticonvulsive treatment. All patients were treated with oseltamivir, methylprednisolone (10mg/kg.d), and gammaglobulin (1g/kg.d*2d) immediately after diagnosis. Twenty-four patients were ventilated with tracheal intubation due to central respiratory failure, and were given mannitol, concentrated sodium, and nutritional support therapy. After the above treatment, 39.7% (27/68) of patients recovered, 39.7% (27/68) developed sequelae, and 20.6% (14/68) died.
The multiple logistic regression analysis showed that high levels of ALT (OR=0.951 (95% CI 0.920-0.982)), AST (OR=1.047 (95% CI 1.017-1.077)), LDH (OR=0.994 (95% CI 0.988-0.999)), and CSF protein (OR=4.385 (95% CI 1.432-13.425)) were high risk factors for death from IAE (Table 2).

**Table 1:** Demographics and clinical characteristics of the children with IAE.

|                          | Total n=68 Number (%/IQR) | Survivors n=54 Number (%/IQR) | Non-survivors n=14 Number (%/IQR) | P-value* |
|--------------------------|----------------------------|-------------------------------|-----------------------------------|----------|
| **Gender**               |                            |                               |                                   |          |
| Male                     | 40 (58.82)                 | 33 (61.11)                    | 7 (50)                            | 0.5468   |
| **Age**                  |                            |                               |                                   |          |
| ≤5 years old             | 45 (66.18)                 | 37 (68.52)                    | 8 (57.14)                         | 0.5288   |
| **Clinical manifestations** |                          |                               |                                   |          |
| Fever >39                | 42 (61.76)                 | 28 (51.85)                    | 14 (100)                          | 0.0005   |
| time of fever lasting (days) | 3 (1-22)                  | 4 (1-22)                      | 3 (1-17)                          | 0.43     |
| Respiratory symptoms     | 30 (44.12)                 | 23 (42.59)                    | 7 (50)                            | 0.5586   |
| Convulsion               | 48 (33.30)                 | 36 (30.30)                    | 12 (36.70)                        |          |
| Less than 3 times        | 24 (64.71)                 | 18 (66.67)                    | 6 (57.14)                         | 0.5415   |
| More than 3 times        | 24 (35.29)                 | 18 (33.33)                    | 6 (42.86)                         |          |
| Headache                 | 12 (17.65)                 | 11 (20.37)                    | 1 (7.14)                          | 0.4351   |
| Vomiting                 | 22 (32.35)                 | 16 (26.93)                    | 6 (42.86)                         | 0.3595   |
| Fatigue                  | 19 (27.94)                 | 17 (31.48)                    | 2 (14.29)                         | 0.3186   |
| ADOD                     | 36 (52.90)                 | 22 (36.70)                    | 14 (100)                          | <0.0001  |
| Cardiac arrest           | 6 (8.2%)                   | 1 (1.85)                      | 5 (35.7)                          | 0.001    |
| **Routine blood test**   |                            |                               |                                   |          |
| Leukocyte (×10^9/L)      | 8.55 (2.4-29.6)            | 8.5 (2.4-29.6)                | 8.8 (3.2-21.7)                    | 0.8837   |
| Lymphocytes (×10^9/L)    | 1.89 (0.32-16.01)          | 2.03 (0.32-16.01)             | 1.55 (0.38-5.1)                   | 0.4105   |
| Monocyte (×10^9/L)       | 0.58 (0.06-3.45)           | 0.6 (0.15-3.45)               | 0.38 (0.06-0.97)                  | 0.08     |
| **Comprehensive metabolic panel Serum** |                |                               |                                   |          |
| ALT (U/L)                | 33 (9-7304)                | 28.5 (9-1885)                 | 70 (13-7304)                      | 0.0074   |
| AST (U/L)                | 69 (19-16770)             | 51.5 (19-1681)                | 176 (43-16770)                    | <0.0001  |
| CK (U/L)                 | 248 (28-16549)            | 204 (28-16549)                | 669 (86-9350)                     | 0.0069   |
| LDH (U/L)                | 357 (197-11962)           | 322 (197-2495)                | 870 (332-11962)                   | <0.0001  |
| CRP (mg/dL)              | 5 (0-141.95)              | 3.78 (0-141.95)               | 11.35 (2.43-128.06)               | 0.037    |
| Lactate (mmol/L)         | 1.7 (0.5-11.1)            | 1.6 (0.5-6.4)                 | 2.45 (1-11.1)                     | 0.0036   |
| **CSF**                  |                            |                               |                                   |          |
| Protein (g/L)            | 0.44 (0.12-34.5)          | 0.34 (0.12-12.4)              | 1.895 (0.12-34.5)                 | <0.0001  |
| Leukocyte (×10^6/L)      | 6 (0-350)                 | 6 (0-350)                     | 9 (1-28)                          | 0.919    |
| **Pathogenetic test**    |                            |                               |                                   |          |
| FA                       | 43 (63.2)                 | 35 (64.8)                     | 8 (57.1)                          | 0.7569   |
| FB                       | 25 (38.5)                 | 19 (35.2)                     | 6 (42.9)                          |          |
| **Treatments**           |                            |                               |                                   |          |
| Oseltamivir              | 68 (100.00)               | 54 (100.00)                   | 14 (100.00)                       | 1        |
| Gammmaglobulin           | 68 (100.00)               | 54 (100.00)                   | 14 (100.00)                       | 1        |
| Methylprednisolone       | 68 (100.00)               | 54 (100.00)                   | 14 (100.00)                       | 1        |
| Ventilator-assisted ventilation | 24 (35.29)       | 12 (22.22)                    | 12 (85.71)                        | <0.0001  |

**Mortality risk factors**

The multiple logistic regression analysis showed that high levels of ALT (OR=0.951 (95% CI 0.920-0.982)), AST (OR=1.047 (95% CI 1.017-1.077)), LDH (OR=0.994 (95% CI 0.988-0.999)), and CSF protein (OR=4.385 (95% CI 1.432-13.425)) were high risk factors for death from IAE (Table 2).

**Discussion**

Influenza is a common infectious disease worldwide [13]. While mainly invading the respiratory tract, influenza viruses can cause neurological damage in some cases, leading to a series of neurological syndromes. The morbidity and mortality rates of neurological damages due to influenza are high, especially in children [4,14], and...
A 3-year-old boy with influenza-related encephalopathy, fever for 2 days and convulsion once. Bilateral dorsal thalamus and basal ganglia were swollen. Multiple asymmetrically patch like abnormal signal shadows were observed in bilateral dorsal thalamus (▲), basal ganglia (*), external capsule (white arrow) and corpus callosum (black arrow), with blurred edges. Axial T1WI (Figure A) showed slightly lower signal intensity, while T2WI (Figure C) and T2WI-FLAIR (Figure D) showed high signal intensity. Contrast-enhanced scan (Figure D) showed no enhancement in the lesion and slightly increased shadow of small vessels on the brain surface.

Figure 1: A 3-year-old boy with acute necrotizing encephalitis, with fever for 2 days and convulsion once. Bilateral dorsal thalamus and basal ganglia were swollen. Multiple asymmetrically patch like abnormal signal shadows were observed in bilateral dorsal thalamus (▲), basal ganglia (*), external capsule (white arrow) and corpus callosum (black arrow), with blurred edges. Axial T1WI (Figure A) showed slightly lower signal intensity, while T2WI (Figure C) and T2WI-FLAIR (Figure D) showed high signal intensity. Contrast-enhanced scan (Figure D) showed no enhancement in the lesion and slightly increased shadow of small vessels on the brain surface.

Table 2: Results of the multivariate analysis of the mortality risk factors in children with IAE.

| Indicator       | OR (OR 95% CI) | P     |
|-----------------|----------------|-------|
| ALT             | 0.951 (0.920-0.982) | 0.002 |
| AST             | 1.047 (1.017-1.077) | 0.002 |
| LDH             | 0.994 (0.988-0.999) | 0.015 |
| CSF protein     | 4.385 (1.432-13.425) | 0.01  |

The results indicate that children under 5 years of age with influenza are prone to combine neurological complications and have a higher mortality rate, significant elevations in ALT, AST, LDH, and CSF proteins predict death from influenza-associated encephalopathy in children.

It has been previously reported that influenza in children at a younger age or with underlying diseases is more likely to combine neurological complications; especially in children younger than 5 years of age [16-18]. In this study, 66.18% (45/68) of the patients were ≤5 years old, which is consistent with the reports. All patients in this study were previously healthy and without underlying diseases. Therefore, it should be given close attention when the onset of neurological symptoms in influenza in healthy children. In this study, we find that the onset of IAE occurred mainly from December to March, which is consistent with the high influenza season. It is currently unknown whether influenza vaccines can prevent IAE or reduce the disease’s extent. There is a report showing that patients with IAE were unvaccinated against influenza [19]. In this study, none of the 68 patients were vaccinated against influenza, suggesting the potential importance of influenza vaccine for children, and therefore vaccination of healthy preschool children in the pre-high influenza season is necessary.

Influenza-associated encephalopathy lacks specific clinical manifestations, and convulsions and impaired consciousness have been previously reported as the most common neurological symptoms of influenza-associated encephalopathy [6]. The main clinical manifestations of the cases in this study are fever, convulsions, ADOC, and respiratory symptoms could be mild or even absent. Moreover, the number of convulsions in the non-survival group did not differ from that in the survival group, indicating that the number of convulsions cannot be used to indicate disease severity.

Previous studies have reported that IAE is mainly caused by influenza virus type A, especially H1N1 [2,20,21]. In this study, we detected influenza virus type A at 36.3% (43/68) in the patients and influenza virus type B at 36.8% (25/68), showing that influenza virus type A is the primary infection source of IAE. However, there was no significant difference in the pathogenic distribution between the non-survival and survival groups, indicating that influenza virus type B may be causing relatively minor neurological damage, but leading to death in severe cases.

Some laboratory tests were found to be markedly abnormal in this study, such as reduced platelets, elevated ALT, AST, CK, LDH, and CSF proteins level. The above indicators were more abnormal in the non-survival group than the survival group, which was statistically significant. Furthermore, Logistic regression analysis showed that elevated ALT, AST, LDH, and CSF protein were independent risk factors of IAE.
Elevated ALT, AST, LDH, and CSF proteins are high risk factors for neurological complications of influenza. The typical brain MRI manifestations of children with IAE were previously reported symmetrical abnormalities of bilateral thalamus, basal ganglia area, medulla oblongata, and pons [20,25,26], which is consistent with the present study. The brain MRI of pediatric IAE is specific and contributes to the disease’s early diagnosis.

The pathogenesis of IAE is still unclear, and it is generally believed that it may result from immune damage or direct viral invasion. Similar to previous studies reported [19], few patients in this study had elevated CSF leukocytes. At the same time, CSF protein was elevated in this study, and it was significantly higher in the non-survival group compared with the survival group, while logistic analysis showed elevated CSF protein as a high-risk factor for death in IAE. This suggests that neurological injury may be immune-mediated, or direct viral invasion, or vascular inflammation, rather than a simple inflammatory response. However, whether influenza viruses can invade the nervous system is controversial, and some studies have reported positive results for viral RNA in CSF and brain tissue in only a few patients [27]. As reported, all patients in this study had negative results for influenza virus RNA on CSF.

There is no standard treatment protocol for IAE, and currently used protocols include antiviral therapy, immunotherapy (pulse therapy with corticosteroids, immunoglobulins), plasma replacement with corticosteroids and immunoglobulins, plasma replacement, and antiviral therapy with corticosteroids, immunoglobulins), plasma replacement with corticosteroids, immunoglobulins, antivirals, and hypothermia, but it is unclear which protocol is more effective [28-31]. For oseltamivir inhibiting the viral expression and reducing the inflammation, some studies report that antiviral therapy may be effective, while guidelines of Infectious Diseases Society of America recommend oseltamivir in the presence of IAE [32]. Although pulse therapy with corticosteroids and immunoglobulins remains controversial, it is currently used widely in clinical practice, for considering IAE is related to immune-mediated damage to the nervous system. All cases in this study were given oseltamivir, and pulse therapy with corticosteroids and immunoglobulins after diagnosis of influenza infection, so it was impossible to compare the difference in efficacy between the survival and non-survival groups.

Our study presents several limitations. The present study is a single-center retrospective analysis with a relatively small number of cases and a lack of long-term assessment in children, which has limitations, and more studies are needed to address these issues.

**Conclusion**

In conclusion, IAE should be considered when neurological symptoms are present for influenza in children under 5 years of age. Elevated ALT, AST, LDH, and CSF proteins are high risk factors for death from IAE. Future larger studies are needed to understand the pathogenesis of IAE, explore biomarkers for assessing neurological involvement and disease severity, and follow the long-term prognosis of the disease.

**Author Contributions**

YL Song, TX Qiu and WQ Xiao carried out the studies, participated in collecting data, and drafted the manuscript; SY Li, Y Hong and Q Wang performed the statistical analysis and participated in its design; QL Chen and XW Fan participated in acquisition, analysis, or interpretation of data; PQ Li reviewed revised manuscripts. All authors read and approved the final manuscript.

**References**

1. Britton PN, Dale RC, Blyth CC, Macartney K, Crawford NW, Marshall H, et al. Influenza-associated Encephalitis/Encephalopathy Identified by the Australian Childhood Encephalitis Study 2013-2015. The Pediatric infectious disease journal. 2017; 36: 1021-1026.
2. Yildizdas D, Kendirli T, Arslankoylu AE, Horoz OO, Inceik F, Ince E, et al. Neurological complications of pandemic influenza (H1N1) in children. Eur J Pediatr. 2011; 170: 779-788.
3. Wang GF, Li W, Li K. Acute encephalopathy and encephalitis caused by influenza virus infection. Curr Opin Neurol. 2010; 23: 305-311.
4. Akins PT, Belko J, Uyeji TM, Axelrod Y, Lee KK, Silverthorn J. H1N1 encephalitis with malignant edema and review of neurologic complications from influenza. Neurocrit Care. 2010; 13: 396-406.
5. Morishima T, Togashi T, Yokota S, Okuno Y, Miyazaki C, Tashiro M, et al. Collaborative Study Group on Influenza-Associated Encephalopathy in Japan: Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2002; 35: 512-517.
6. Paksu MS, Aslan K, Kendirli T, Akyildiz BN, Yener N, Yildizdas RD, et al. Neuroinfluenza: evaluation of seasonal influenza associated severe neurological complications in children (a multicenter study). Childs Nerv Syst. 2018; 34: 335-347.
7. San Millan B, Tejeira S, Penin C, Garcia JL, Navarro C. Acute necrotizing encephalopathy of childhood: report of a Spanish case. Pediatric neurology. 2007; 37: 438-441.
8. Tabarki B, Thabet F, Al Shafi S, Al Awadi N, Chehab M, Al Shahwan S. Acute necrotizing encephalopathy associated with enterovirus infection. Brain & development. 2013; 35: 454-457.
9. Aydin H, Ozgul E, Agidere AM: Acute necrotizing encephalopathy secondary to diphtheria, tetanus toxoid and whole-cell pertussis vaccination: diffusion-weighted imaging and proton MR spectroscopy findings. Pediatr Radiol. 2010; 40: 1281-1284.
10. Sugaya N. Influenza-associated encephalopathy in Japan. Seminars in pediatric infectious diseases. 2002; 12: 79-84.
11. Shiono M. [Pathogenesis of acute encephalitis and acute encephalopathy]. Nihon rinsho, Japanese journal of clinical medicine. 2011; 69: 399-408.
12. Howard A, Uyeji TM, Fergie J. Influenza-Associated Acute Necrotizing Encephalopathy in Siblings. Journal of the Pediatric Infectious Diseases Society. 2018; 7: e172-e177.
13. Aziz Baumgartner E, Diao CN, Nasreen S, Bhuiyan MA, Mah EMS, Al Mamun A, et al. Seasonality, timing, and climate drivers of influenza activity worldwide. The Journal of infectious diseases. 2012; 206: 838-846.
14. Wong KK, Jain S, Blanton L, Dhara R, Brammer L, Fry AM, et al. Influenza-associated pediatric deaths in the United States, 2004-2012. Pediatrics. 2013; 132: 796-804.
15. Okuno H, Yahata Y, Tanaka-Taya K, Arai S, Satoh H, Morino S, et al. Characteristics and Outcomes of Influenza-Associated Encephalopathy Cases Among Children and Adults in Japan, 2010-2015. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017; 64: 1493-1499.
16. Wada T, Morishima T, Okumura A, Tashiro M, Hosoya M, Shiomi M, et al. Differences in clinical manifestations of influenza-associated encephalopathy by age. Microbiology and immunology. 2009; 53: 83-88.
17. Havers F, Fry A, Peacock G, Finelli L. Influenza vaccination and treatment in children with neurologic disorders. Ther Adv Vaccines. 2014; 2: 95-105.
18. Wilking AN, Elliott E, Garcia MN, Murray KO, Munoz FM. Central nervous system manifestations in pediatric patients with influenza A H1N1 infection during the 2009 pandemic. Pediatric neurology. 2011; 51: 370-376.
19. Kedia S, Stroud B, Parsons J, Schreiner T, Curtis DJ, Bagdure D, et al. Pediatric neurological complications of 2009 pandemic influenza A (H1N1). Arch Neurol. 2011; 68: 455-462.
20. Turgut M, Sagiroglu S. Suboccipital decompressive craniectomy in a case of complex Chiari malformation complicated with influenza A (H1N1) necrotizing encephalopathy. Childs Nerv Syst. 2020; 36: 1335-1336.
21. Teke T, Coskun R, Sungur M, Guven M, Bekci TT, Maden E, et al. 2009 H1N1 influenza and experience in three critical care units. Int J Med Sci. 2011; 8: 270-277.
22. Nagao T, Morishima T, Kimura H, Yokota S, Yamashita N, Ichiyama T. Prognostic factors in influenza-associated encephalopathy. The Pediatric Infectious Disease Journal. 2008; 27: 384-389.
23. Li S, Hu D, Li P, Xiao W, Li H, Liu G, et al. Parameters Indicating Development of Influenza-Associated Acute Necrotizing Encephalopathy: Experiences from a Single Center. Med Sci Monit. 2021; 27: e930688.
24. Song Y, Li S, Xiao W, Shen J, Ma W, Wang Q, et al. Influenza-Associated Encephalopathy and Acute Necrotizing Encephalopathy in Children: A Retrospective Single-Center Study. Med Sci Monit. 2021; 27: e928374.